Analyst firms · Oppenheimer · NKTR
Oppenheimer NKTR price target and rating history
Nektar Therapeutics (NKTR) · Health Care
Oppenheimer rates Nektar Therapeutics (NKTR) Outperform with a $6 price target, as of its latest action on Mar 14, 2025. It has published 3 rating actions on NKTR since November 2021, including 2 upgrades and 0 downgrades. Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.
- Current rating
- Outperform
- Price target
- $6
- Median target, all firms
- $102
- Actions on NKTR
- 3
Oppenheimer price target on NKTR
Every Oppenheimer rating on NKTR
- Mar 14, 2025
- Mar 9, 2022
- Nov 5, 2021
How other firms rate NKTR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $53 | Oct 12, 2026 |
| Leerink Partners | Outperform | $130 | Oct 12, 2026 |
| Raymond James | Mkt Perform | Oct 9, 2026 | |
| Canaccord Genuity | Buy | $153 | Jul 22, 2026 |
| Wedbush | Neutral | $70 | Mar 24, 2026 |
| TD Cowen | Buy | Mar 17, 2026 | |
| William Blair | Outperform | Feb 10, 2026 | |
| Citigroup | Buy | $102 | Nov 26, 2025 |
Questions about Oppenheimer and NKTR
- What is Oppenheimer's price target for NKTR?
- Oppenheimer's latest stated price target for Nektar Therapeutics (NKTR) is $6, from its action on Mar 14, 2025.
- What is Oppenheimer's rating on NKTR?
- Oppenheimer rates NKTR Outperform, a bullish rating, as of Mar 14, 2025.
- When did Oppenheimer last change its view on NKTR?
- On Mar 14, 2025, Oppenheimer upgrades to Outperform from Perform, price target $6.
- How does Oppenheimer's NKTR target compare with other analysts?
- Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.
More NKTR rating histories
All Oppenheimer ratingsNKTR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.